Tag Archives: innovation

New Institute for Immunologic Intervention (3i) at the Hackensack … – Hackensack Meridian Health

The new Institute aims to harness and boost immunity to tackle health puzzles - and is already supported by a generous gift from a donor

The Hackensack Meridian Center for Discovery and Innovation (CDI) has formed a new institute aiming to fight infections, cancer, and inflammatory diseases by finding a better way to restore and bolster the human immune system in its responses to disease.

The Institute for Immunologic Intervention (or 3i) is searching for ways to unleash new advances in immunology to beat disease and save lives. The expert scientists in this new institute include basic researchers, physician-scientists, and leading clinicians who are working seamlessly to tackle major health problems of our time.

The Institute is dedicated to advancing the understanding of fundamental mechanisms of infectious immunity, tumor immunity, alloimmunity, and autoimmunity within clinical contexts. By fostering collaborations with the CDI, the John Theurer Cancer Center at Hackensack University Medical Center and its consortium partner Georgetown Universitys Lombardi Comprehensive Cancer Center, and beyond, the 3i strives to apply this knowledge towards innovative strategies that enhance the effectiveness of cancer immunotherapy, interventions for autoimmune and alloimmune conditions, and the prevention of infections.

We have recruited world-class talent to give this Institute critical mass, said David Perlin, Ph.D., chief scientific officer and executive vice president of the CDI, and professor of medical sciences at the Hackensack Meridian School of Medicine. These scientists are tackling disease at the basic level of discovery - but with an eye toward finding real-world solutions in the near future. This is what the CDI is all about. Perlin is also a professor at Georgetown University.

We are excited about the possibilities - and also about the collaborations already happening among this group of scientists, said Binfeng Lu, Ph.D., the director of the 3i.

The scientists whose work is critical to the 3i, and their fields of expertise, include: Lu: cancer immunology and immunotherapy, and inflammatory biology; Yi Zhang, M.D., Ph.D.: (CAR) T cell biology, tumor immunity and alloimmunity; Hai-Hui Howard Xue, M.D., Ph.D.: T cell biology, tumor immunity; Johannes Zakrzewski, M.D.: cancer immunotherapy and immunosurveillance; Rachel Rosenstein, M.D., Ph.D.: inflammatory and fibrotic diseases; Sivia Lapidus, M.D., M.D.: pediatric rheumatic conditions and autoinflammatory disorders; Jigar V. Desai, Ph.D.: innate immunity, fungal infections; Benjamin Tycko, M.D., Ph.D.: genetics and epigenetics in human development and disease; Rena Feinman, Ph.D.: influence of the gut microbiome on antitumor immunosurveillance in patients with multiple myeloma (MM); Kevin Tong, Ph.D.: modeling the genetic progression of colorectal cancer for targeted therapies and personalized medicine; and Alvin Makohon-Moore, Ph.D.: evolutionary dynamics of cancer.

Virtually all of these 3i scientists also have faculty appointments at the Hackensack Meridian School of Medicine.

The research cores supporting the 3i include flow cytometry, microscopy, tissue biorepository bank, bioinformatics and statistical analysis, gene-editing, computational chemistry, and clinical immunology assays, among other expertise.

The expertise brought together in this one Institute at the CDI is a thrilling development, said Ihor Sawczuk, M.D., FACS, president of Academics, Research and Innovation for Hackensack MeridianHealth, the founding chair of the Hackensack MeridianHealthResearch Institute (HMHRI) of which CDI is part, and also associate dean of clinical integration and professor and chair emeritus of urology at the Hackensack Meridian School of Medicine. Working across an ecosystem like this is what will drive our science forward.

The 3i laboratories are all supported by federal grants. Most recently, in support of this mission, the 3i received a philanthropic grant in the amount of $500,000 to support the Institutes work in immunology and multiple myeloma research from the DAloia Family Foundation, led by G. Peter DAloia, an accomplished business executive who previously worked at several large national corporations, and his wife Marguerite. Mr. D'Aloia previously made a major gift to Hackensack Meridian Ocean University Medical Center.

I believe that the CDI has a great approach to finding cures for some of todays most difficult diseases, in particular its work on using the bodys immune system to fight cancer and its focus on treatment and cures for multiple myeloma, said Peter DAloia. It is my hope that this gift provides meaningful help in allowing the CDI to continue the good work being done within the organization.

To make a gift in support of the Institute for Immunologic Intervention (3i) at CDI, please visitGiveHMH.org/CDIor call William Evans, executive director at the CDI, atwilliam.evans@hmhn.orgor 201-880-3100.

Original post:
New Institute for Immunologic Intervention (3i) at the Hackensack ... - Hackensack Meridian Health

Urbanization Boosts Brain Size in Modern Dog Breeds – Neuroscience News

Summary: Modern dog breeds, which are genetically farther from wolves, have relatively larger brain sizes compared to ancient breeds. The increase in brain size is not related to the specific roles or life history characteristics of the breeds, indicating that its likely influenced by urbanization and a more complex social environment.

The study revealed that the further a dog breed is genetically distant from wolves, the larger its relative brain size becomes.

This study provides new insight into the rapid evolution and diversity within the dog species, possibly due to their adaptation to human environments and social complexity.

Key Facts:

Source: ELTE

Modern dog breeds that are genetically more distant from wolves have a relatively larger brain size compared to ancient breeds that are thousands of years old, according to the findings of Hungarian and Swedish researchers.

The increase in brain size cannot be attributed to the roles or life history characteristics of the breeds, suggesting that it is likely influenced by urbanization and a more complex social environment.

Even today, the known four hundred dog breeds have developed relatively quickly and exhibit great diversity, making them a treasure trove for researchers interested in rapid changes within a species.

Scientists have long been curious about the factors that affect brain size because the human brain is unusually large in comparison to body size.Comparing the various dog breeds can help answer some questions.

Is there a correlation between brain size and the specific tasks for which a breed was bred?

Are there differences, for example, between lap dogs and hunting dogs? Or is it more influenced by life expectancy and the challenges of offspring rearing?What we know for certain is thatthinking and cognitive processes require a lot of energy, and maintaining a larger brain is costly.

Lszl Zsolt Garamszegi,an evolutionary biologist at the Ecological Research Centre in Hungary, has been studying the evolution of brain size for a long time.

The brains of domesticated animals can be up to twenty percent smaller than those of their wild ancestors. The likely reason for this is that the lives of domesticated species are simpler compared to those of their wild counterparts. In the safe environment provided by humans, there is no need to fear predator attacks or hunt for food.

Therefore, there is no need to sustain the energetically costly large brain, and the freed-up energy can be directed towards other purposes, such as producing more offspring, which is important for domesticated animals, she said.

Niclas Kolm, at Stockholm University, focuses on brain evolution and the link between variation in brain morphology and behavior.

Different dog breeds live in varying levels of social complexity and perform complex tasks, which likely require a larger brain capacity.

Therefore, we hypothesize that the selective pressures on the brain can vary within the dog species, and we may find differences in brain size among breeds based on the tasks they perform or their genetic distance from wolves.

This is the first comprehensive study regarding the brain size of different dog breeds, and its preparation took several decades.

Tibor Csrg, a senior research fellow at the Department of Anatomy, Cell and Developmental Biology at Etvs Lornd University (ELTE), has been collecting skulls for decades. CT scans of the skulls were performed by Medicopus Nonprofit Ltd. in Kaposvr.

Based on the CT images, veterinarianKlmn Czeibertreconstructed the brains and determined their exact volume. This invaluable collection was complemented by the Canine Brain and Tissue Bank, operated by ELTE for the past seven years, which enabled the verification of brain volumes calculated from skull images using actual brains. In the end, data was gathered from 865 individuals representing 159 dog breeds, with 48 specimens representing wolves.

According to the results published in the journalEvolution,wolves have an average brain volume of 131 cm3, associated with an average body weight of 31 kg. In the case of dogs in a similar weight category, the brain volume is only about three-quarters of that, approximately 100 cm3.

This confirms that domestication has also led to a decrease in brain size in dogs. However, what surprised researchers is that the further a dog breed is genetically distant from wolves, the larger its relative brain size becomes.

Contrary to expectations, the original role of the breeds, average litter size, and life expectancy are independent of brain size.

The domestication of dogs began approximately twenty-five thousand years ago, but for ten thousand years, dogs and wolves did not differ in appearance. Many ancient breeds, such as sled dogs, still resemble wolves today.

However, the transition to settlement, agriculture, pastoralism, and the accumulation of wealth offered various tasks for dogs, requiring guard dogs, herding dogs, hunting dogs, and even lap dogs.

A significant portion of the distinct-looking breeds known today has only emerged since the industrial revolution, primarily in the last two centuries, as dog breeding has become a kind of hobby, saysEnik Kubinyi, a senior research fellow at the Department of Ethology at ELTE.

The results show that the breeding of modern dog breeds has been accompanied by an increase in brain size compared to ancient breeds. We couldnt explain this based on the tasks or life history characteristics of the breeds, so we can only speculate about the reasons.

Perhaps the more complex social environment, urbanization, and adaptation to more rules and expectations have caused this change, affecting all modern breeds.

These findings are supported by research indicating that ancient breeds known for their independence are less attentive to human cues and bark less, thus exhibiting differences in visual and acoustic communication compared to modern breeds.

Funding: The study was supported by the Hungarian Academy of Sciences via a grant to the Hungarian Academy of Sciences (grant no. PH1404/21) and National Brain Programme 3.0 (NAP2022-I-3/2022), and by the National Research, Development and Innovation Office (grant no. 2019-2.1.11-TT-2020-00109) and Swedish Research Council (grant no. 2021-04476).

Author: Sara BohmSource: ELTEContact: Sara Bohm ELTEImage: The image is credited to Neuroscience News

Original Research: Open access.Evolution of relative brain size in dogsno effects of selection for breed function, litter size, or longevity by Lszl Zsolt Garamszegi et al. Evolution

Abstract

Evolution of relative brain size in dogsno effects of selection for breed function, litter size, or longevity

Domestication is a well-known example of the relaxation of environmentally based cognitive selection that leads to reductions in brain size. However, little is known about how brain size evolves after domestication and whether subsequent directional/artificial selection can compensate for domestication effects.

The first animal to be domesticated was the dog, and recent directional breeding generated the extensive phenotypic variation among breeds we observe today.

Here we use a novel endocranial dataset based on high-resolution CT scans to estimate brain size in 159 dog breeds and analyze how relative brain size varies across breeds in relation to functional selection, longevity, and litter size. In our analyses, we controlled for potential confounding factors such as common descent, gene flow, body size, and skull shape.

We found that dogs have consistently smaller relative brain size than wolves supporting the domestication effect, but breeds that are more distantly related to wolves have relatively larger brains than breeds that are more closely related to wolves.

Neither functional category, skull shape, longevity, nor litter size was associated with relative brain size, which implies that selection for performing specific tasks, morphology, and life history does not necessarily influence brain size evolution in domesticated species.

See the rest here:
Urbanization Boosts Brain Size in Modern Dog Breeds - Neuroscience News

Eye-Opening Drug Discovery May Help Treat Age-Related Macular … – Neuroscience News

Summary: 350 million people worldwide are believed to suffer from blinding diseases including age-related macular degeneration and diabetic retinopathy.

Researchers have discovered small-molecule drugs that could be used to treat age-related macular degeneration, diabetic retinopathy, and retinitis pigmentosa. The drugs, called stress resilience-enhancing drugs (SREDs), slowed or halted the progression of retinopathies in animal models by inhibiting cyclic nucleotide phosphodiesterases.

Key Facts:

Source: UC Irvine

In a University of California, Irvine-led study, researchers have discovered small-molecule drugs with potential clinical utility in the treatment of age-related macular degeneration (AMD), diabetic retinopathy (DR), and retinitis pigmentosa (RP).

The study, titled, Stress resilience-enhancing drugs preserve tissue structure and function in degenerating retina via phosphodiesterase inhibition, was published in theProceedings of the National Academy of Sciences.

In this study, we introduce a new class of therapeutics called Stress Resilience-Enhancing Drugs (SREDs) for the treatment of neurodegenerative conditions, specifically the worlds leading causes of blindness in age-related and inheritedretinal diseases, said Krzysztof Palczewski, Ph.D., Donald Bren Professor of Ophthalmology at the UCI School of Medicine and corresponding author on the study.

Through selective, pharmacological inhibition of cyclic nucleotide phosphodiesterases, our prototypical SREDs slowed or halted the development and progression of retinopathies in a number of genetic and environmental animal models.

Today, approximately 350 million people worldwide suffer from debilitating vision loss caused by either AMD or DR, and a large majority of these cases (>90%) have only minimally effective or notreatment optionsavailable. These chronic, progressive retinal diseases, including retinitis pigmentosa, arise from genetic and environmental disruptions of cellular and tissue stability.

Such disruptions accumulate with repeated exposures to stress over time, leading to progressive visual impairment and, in many cases, legal blindness.

Despite decades of research, therapeutic options for the millions of patients suffering from these disorders remain severely limited, especially for treating earlier stages of disease when the opportunity to preserve the retinal structure and visual function is greatest.

To address this urgent, unmet medical need, the researchers in this study innovated a systems pharmacology platform that leverages state-of-the-art disease modeling and characterization to identify novel, mechanism-based therapies that mitigate disease at the root cause.

The SRED therapeutic intervention enhanced resilience to acute and chronic forms of stress in the degenerating retina, thus preserving tissue structure and function across multiple models of age-related or inherited retinal disease.

Taken together, these findings exemplify a systems pharmacology approach todrug discoveryand development, revealing a new class of therapeutics with potential clinical utility in the treatment or prevention of the most common causes of blindness.

SREDs represent a promising strategy for patients and clinicians to combat disease in earlier stages with superior efficacy over the current standard of care, augmenting the arsenal of ophthalmic medications presently available in anti-angiogenics, corticosteroids, and nonsteroidal anti-inflammatory drugs (NSAIDs), said lead author Jennings Luu, MD/Ph.D. Doctoral Fellow of Pharmacology in the Medical Scientist Training Program at Case Western Reserve University and Visiting Scholar at University of California, Irvine.

Ultimately, it is our expectation that SREDs will someday serve as a standard of care for human aging, effectively providing patients the means to diminish suffering from debilitating ailments for which there currently exist no viabletherapeutic options, thereby extending human lifespan and healthspan irrespective of disease etiology.

Predicated in part on the discoveries highlighted in this publication, Luu and Palczewski have co-founded a seed-stage startup pharmaceutical company,Hyperion Therapeutics, Inc., which aims to commercialize theintellectual propertyassociated with their recent discoveries and introduce to the market new therapeutic agents for the treatment or prevention of AMD, DR, RP, and other progressive, incurable blinding diseases.

The Company was recently awarded first place in the Morganthaler-Pavey Startup Competition hosted by the Veale Institute for Entrepreneurship and has additionally partnered with UCI Beall Applied Innovation in the Wayfinder Incubator Program; through this strategic alliance, Luu and Palczewski are serving as co-investigators on a newly awarded Proof of Product grant, which will support the advancement of their pipeline therapies toward clinical trials and eventual commercialization.

Author: Press OfficeSource: UC IrvineContact: Press Office UC IrvineImage: The image is credited to Neuroscience News

Original Research: Closed access.Stress resilience-enhancing drugs preserve tissue structure and function in degenerating retina via phosphodiesterase inhibition by Jennings C. Luu et al. PNAS

Abstract

Stress resilience-enhancing drugs preserve tissue structure and function in degenerating retina via phosphodiesterase inhibition

Chronic, progressive retinal diseases, such as age-related macular degeneration (AMD), diabetic retinopathy, and retinitis pigmentosa, arise from genetic and environmental perturbations of cellular and tissue homeostasis. These disruptions accumulate with repeated exposures to stress over time, leading to progressive visual impairment and, in many cases, legal blindness.

Despite decades of research, therapeutic options for the millions of patients suffering from these disorders remain severely limited, especially for treating earlier stages of pathogenesis when the opportunity to preserve the retinal structure and visual function is greatest.

To address this urgent, unmet medical need, we employed a systems pharmacology platform for therapeutic development. Through integrative single-cell transcriptomics, proteomics, and phosphoproteomics, we identified universal molecular mechanisms across distinct models of age-related and inherited retinal degenerations, characterized by impaired physiological resilience to stress.

Here, we report that selective, targeted pharmacological inhibition of cyclic nucleotide phosphodiesterases (PDEs), which serve as critical regulatory nodes that modulate intracellular second messenger signaling pathways, stabilized the transcriptome, proteome, and phosphoproteome through downstream activation of protective mechanisms coupled with synergistic inhibition of degenerative processes.

This therapeutic intervention enhanced resilience to acute and chronic forms of stress in the degenerating retina, thus preserving tissue structure and function across various models of age-related and inherited retinal disease.

Taken together, these findings exemplify a systems pharmacology approach to drug discovery and development, revealing a new class of therapeutics with potential clinical utility in the treatment or prevention of the most common causes of blindness.

Here is the original post:
Eye-Opening Drug Discovery May Help Treat Age-Related Macular ... - Neuroscience News

The COVID ’emergency’ is over. Should I relax precautions or still … – NPR

A poster in Kolkata, India, from peak pandemic days sends a message to mask up. Now that the official COVID-19 global emergency is no longer in effect, some folks are thrilled to stop masking but others wonder if it's a good idea to keep up certain precautions. NurPhoto via Getty Images hide caption

Last Friday, the World Health Organization ended the Public Health Emergency of International Concern that it announced three years ago when the virus that causes COVID-19 became a global threat. And the Centers for Disease Control and Prevention ended its public health emergency, effective May 11.

The FAQ series published in the Goats and Soda blog was a cornerstone of NPR pandemic coverage, touching on everything from transmission via pets (possible but unlikely) to whether a glass of wine after a vaccine is advisable (seems ok). As the world enters a new phase of the pandemic, we talked to public health gurus about how to move forward since the disease appears to be here to stay even as the emergency is lifted. Dear readers, if you have questions about this new phase of the pandemic, write us at goatsandsoda@npr.org and put "FAQ" in the subject line. Please include your name and location. We'll be answering a sampling of questions in a follow-up FAQ.

So remind me, what was the purpose of the emergency state?

Thomas Bollyky, senior fellow for global health, economics and development at the Council on Foreign Relations, says that a public health emergency is "really designed to spur international cooperation around a public health event that is serious, sudden, unexpected and requires immediate attention."

And what makes this an appropriate time to end the emergency state?

Last week when the World Health Organization ended its 3-plus year Public Health Emergency of International Concern, the emergency committee advising the WHO's Director General said it was time to do so because of "the decreasing trend in COVID-19 deaths, the decline in COVID-19 related hospitalizations and intensive care unit admissions, and the high levels of population immunity to SARS-CoV-2 [the virus that causes COVID-19]."

In the U.S., the Centers for Disease Control and Prevention said the U.S. Public Health Emergency was ending because "as a nation, we now find ourselves at a different point in the pandemic with more tools and resources than ever before to better protect ourselves and our communities."

Did those agencies do a good job explaining themselves?

Well, the quotes from the CDC and WHO are clear.

But Bollyky says articulating the targets and goals for the ending the pandemic all along such as how low the case and death counts would need to be to lift mask mandates or school closures would have helped the public understand why the agencies felt that May 2023 was the right time to conclude the public health emergency. "If the public can't see progress, it will be harder to convince them next time that these emergency measures are necessary," says Bollyky.

And how big of a threat is COVID now?

The announcement that the emergency is over doesn't mean the virus been vanquished, says Dr. Wafa El-Sadr, director of the Global Health Initiative at the Mailman School of Public Health at Columbia University. It's still infecting thousands and killing thousands each week.

Then again, so are diseases like malaria and cholera.

And just as we take those diseases seriously, we should take COVID-19 seriously, say the experts.

"HIV doesn't have a public health emergency declaration, tetanus doesn't have a public health emergency declaration, and yet people stay up to date with vaccinations and treatments," says Dr. Amesh Adalja, senior scholar at the Johns Hopkins Center for Health Security, "People don't need a public health emergency to take something seriously."

Nonetheless, the reassuring message from CDC and WHO is that you're less likely to catch COVID-19 because case counts have dropped due to vigilance and treatments.

"WHO now sees COVID-19 as a threat in our regular repertoire of things-trying-to-kill-us," says epidemiologist Katelyn Jetelina. a health policy epidemiologist with the Meadows Mental Health Policy Institute in Dallas, who writes the blog Your Local Epidemiologist. And the truth is that the world now has better tools and treatments for COVID than for some age-old diseases: from the readily available self-tests to vaccines and boosters to the paxlovid pill to lessen severity for higher-risk patients.

So is it ok to just blithely dismiss a case of COVID?

Even if you're an individual with no health risks and you catch the virus, there are things to worry about: just plain feeling awful is possible even if you're not high-risk. You might have to miss work. You run a risk of long COVID. And then there's the possibility you could transmit the virus to others at risk of severe COVID and death from the virus.

And what if you test positive and have risks: say, you're older, immunocompromised or have underlying health conditions such as obesity, heart disease, a compromised immune system or diabetes. Don't just figure you can beat it on your own. Reach out to your doctor right away, says Dr. Aaron Glatt, chair of medicine at Mount Sinai South Nassau in Oceanside, N.Y. "There are effective treatments available for high-risk infected individuals that are underutilized. You may be a candidate, which could reduce your possibility of progressing to severe disease."

For example, there's the COVID antiviral drug paxlovid which has been proven to help. A review of federal data in JAMA Internal Medicine found that the risk of long-term health problems, hospitalization and death after a COVID-19 infection diminishes among those who take the medication within five days after testing positive. That's according to an analysis of federal health data by researchers at Washington University School of Medicine in St. Louis and the Veterans Affairs St. Louis Health Care system.

So then ... is it wise to keep maybe some precautions?

Many physicians interviewed for this story tell us they still take precautions they think warranted. "Professionally, I still wear a mask for most patient care in the clinic and the hospital," says Dr. Luis Ostrosky-Zeichner, chief epidemiology officer at the Memorial Hermann Healthcare System in Dallas.

"In my personal life," he adds, "I still have A Purell dispenser in my car and carry a small bottle when I travel. I wear a mask in the airport and until the plane takes off since I'm less exposed in my own seat and [because of] the plane's ventilation system and then put it on again and wear it until I get to my hotel room. And yes, I still have tests at home and travel with a pair of them."

And while many many people are glad to doff masks forever and plunge back into the madding crowds in transportation hubs, concert arena and sports venues, others are understandably ... nervous.

If you don't have underlying conditions that put you at risk and feel uncertain about how to proceed, have an honest converation with your doctor or health-care provider, suggests Dr. Preeti Malani, a professor of medicine in the Divisions of Infectious Diseases and Geriatric Medicine at the University of Michigan. Ask how to gauge your personal risk.

Malani does believe that too much worry is not good for you: Fear of COVID or severe anxiety out of proportion to risk can lead to depression and other mental health concerns, says Malani.

So she's a champion of being realistic rather than fatalistic.

"We have the tools to mitigate and manage risk so that we can do all the things that are important to us," says Malani. She notes that people should keep in mind that masks work well especially when they are worn, if needed, and you are fully vaccinated. And it may be reassuring to have a plan for testing and treatment if needed.

So the idea is, to mask or not to mask ... it's up to me?

You are the keeper of your own health and the best authority on your own risk factor.

It is worth noting that even though masks were often deemed ineffective in the U.S. in the early days of the pandemic, global evidence shows that N-95s and KN-95s worn properly do reduce your risk of contracting COVID (not to mention the flu and other respiratory ailments). And the U.S. did eventually embrace masks.

You may still need to mask up in certain places, like health-care faciliites although rules are changing, with many hospitals and doctors offices ending the requirement for staff and patients. But that doesn't mean you have to take yours off. And if you're concerned you can ask maskless staff that interact with you to put one on. (And if you see a carelessly worn mask, you can muster up your best public-health voice and remark a mask should go above the nose.)

And ... keep getting those boosters, right? Or maybe not so necessary if it's not an emergency?

The rapid development of effective COVID vaccines around the world has been a medical marvel. There will be periodic new boosters available. But don't necessarily expect to be prodded on your cellphone one NPR reporter just got a message that his vaccine reminders will cease.

So with the emergency state over, you may have to pay attention to your own vaccine schedule rather than hearing calls from the government to go get your booster.

And public health specialists note that you shouldn't just focus on COVID when it comes to vaccines. "Learn about and stay up to date on all vaccines," says Dr. William Schaffner, medical director of the National Foundation for Infectious Diseases. The first-ever vaccine for adults to prevent respiratory syncytial virus (RSV) is expected to be available by September in the U.S.. Then there are easonal flu shots and likely a new COVID booster. "Adults will want to talk to their doctors this fall about all the vaccines they need," he says.

Are there any surprising lessons from this emergency?

Loneliness sucks more than you can imagine. Yeah, well maybe that's not a big surprise but the pandemic reinforced the toll that a lack of social contacts can take on mental health.

Dr. Malani is the lead researcher on a January 2023 survey of more than 2,500 people ages 50 to 80 conducted by the University of Michigan Institute for Healthcare Policy and Innovation and supported by AARP and Michigan Medicine. The survey found that one in three people between the ages of 50 and 80 say they sometimes or often experience loneliness.

That's down from about half of older adults in June 2020, when remaining at home was advocated in order to help prevent contracting COVID-19. But it's still noteworthy, says Malani: "If anything, the pandemic has shown us just how important social interaction is for overall mental and physical health and how much more attention we need to pay to this from a clinical, policy and personal perspective."

She says that even for people at risk of severe disease from COVID-19 there are precautions to take to help avoid isolation including online conversations, meeting outdoors where risk of transmission is lower, continued masking and especially talking to your doctor to get a clear sense of your risk of severe disease.

"Some people who were treated for cancer years ago continue to worry that they are at high risk," says Malani. "A talk with your doctor can help you determine risk and precautions to help you engage with people and activities you enjoy." On a personal note, she says she masks when caring for patients but otherwise generally does not mask in meetings or even while traveling these days. "I pay attention to how I feel and am careful about not exposing anyone if I have any symptoms at all, even if mild," she says.

And when should I test for COVID in this post-emergency era?

Consider testing if you have been exposed to someone with the virus or have symptoms that could be COVID-19, especially if you fall into a high risk group, say the doctors we interviewed. And hang onto those masks. You'll want one if someone in your home tests positive so you can protect yourself and protect others if you test positive.

So can you sum it all up for me?

The end of the national emergency around COVID-19 means that there will be certain bureaucratic changes in the way COVID is handled, says Dr. Leana Wen, an emergency physician and professor of health policy and management at George Washington University. For example, she says, there will be less collection and posting of COVID data and fewer requirements for local public health departments to check in with the CDC.

But we're going to be living with COVID-19 for ... a while. Wen, who gave birth to her second child during the pandemic, says "it has become clear that this coronavirus will be with us for the foreseeable future and is an infectious disease that must be prevented, treated, and managed, like other serious conditions. The focus should shift from population-wide measures to safeguarding the most vulnerable and investing in better vaccines and treatments to help those at highest risk from severe outcomes due to COVID-19."

Editor's note: To all the medical professionals who have kindly shared their time and insights to answer questions for the coronavirus FAQ series even as many of them put themselves at risk of infection while caring for patients we offer our heartfelt gratitude.

Read this article:

The COVID 'emergency' is over. Should I relax precautions or still ... - NPR

AIMed Global Summit 2023 to Focus on Changing Healthcare One … – Diagnostic and Interventional Cardiology

May 10, 2023 The AiMed Global Summit will be held June 4-7, 2023, in SanDiego, Calif, and program details offered include a comprehensive agenda of key leaders on artificial intelligence (AI) and its application and implications on healthcare. The event will offer six high-value tracks, 200+ speakers, a dozen keynotes, pre and post summit partner events over three days, offering attendees a chance to gain insights into the latest use cases, perspective and approaches in AI medicine. Participants will also have an opportunity to access the Smart Health Expo, network with 1500 healthcare game changers and hear from top health AI luminaries, facilitating expert insights, proven best practices and real-world success stories, and interact with more than 60 sponsoring exhibitors, according to AiMed Global Summit planners.

An overview of AiMed Global Summit news features and program highlights has been updated by the editorial team at Imaging Technology News/ITN (itnonline.com) and Diagnostic and Interventional Cardiology/DAIC (dicardiology.com) who will be on site and offer ongoing coverage.

Representatives from the following top healthcare facilities across the country have been tapped to speak during the Summit, and include but are not limited to: Tenet Health, Mayo Clinic, University of California, Duke AI Health, Harvard Medical School, Phoenix Childrens, Rady Childrens, University of Texas MD Andersen Cancer Center, and CHOC Childrens.

Additionally, leaders from leading associations are scheduled to participate as Speaker Advisors, including President-Elect of the American Medical Association, Jesse Ehrenfeld, MD, providing An Update from the AMA on June 5, as well as representatives from the American Hospital Association, and the American College of Cardiology.

Major business speakers include: Bayer - Head of Medical Affairs, Digital Radiology, Ankur Sharma;Nuance Chief Medical Information Officer, Matthew Lungren, MD, MPH;AWS Principal Business Devt Officer-Academic Medical Centers, Rod Tarrago, MD;Google Health Chief Clinical Officer, Michael Howell; Clinical Lead, Public & Population Health, Von Nguyen, MD;Philips Global Practice Leader, Edgar Van Zoelen.

During AiMed 2023, content will be split across six dedicated tracks which planners have described as focusing on these areas:

1) From Data to Delivery:Uncovering how data is being leveraged to drive innovation and help change the way clinicians and healthcare business leaders identify, manage and treat patients.

2) Population Health & Equity:Participants of this track will discuss, question and collaborate on developing, validating, and testing AI approaches for risk prediction, bias situations and areas of prevalence, diagnostics and decision making to provide value for cohorts and improving health equity.

3) Ethics & Regulation:With a lens of ensuring humans remain in the loop, discussions explore the nuances of AI so that it promotes well-being, patient equity, human safety and the public interest. This track deep dives into the R.E.A.L (regulation, ethics, accountability and legal) issues around AI and the wider considerations.

4) Tools & Deployment Track:Participants will be able consider use cases and lessons learned to aid your deployment decisions and benefit from the transformational opportunities that AI can provide in medicine and healthcare operations. Dig into the AI tool kit and explore RPA, wearable technology, NLP, digital twins, neural networks, machine and deep learning, extended reality, etc. For those wondering how to implement AI in their roles, scale up, just getting started or already an expert.

5) Strategies for Healthcare Leaders:This track translates these nuances in detail to build sector resilience as we reimagine the future of healthcare with AI. Seeks to answer the question: do we have the policy, strategy, funding models, education and people in place to deliver at scale?

6) Application in Clinical Domains:As the scope increases, providing clinicians with further insights into patient conditions, this track shares the latest applications and use cases across clinical domains.

The College of Healthcare Information Management Executives (CHiME) is hosting the Innovation in Clinical Informatics as part of AiMed Global Summits Pre-Summit Program onon Sunday, June 4 and Monday, June 5.CHiME is the professional organization for Chief Information Officers and other senior healthcare IT leaders. CHiME enables its members and business partners to collaborate, exchange ideas, develop professionally and advocate the effective use of information management to improve the health and care throughout the communities they serve. Learn from leading experts at this jam-packed program led by C-level healthcare executives, delivering the roadmap to implement next-gen solutions in your practice.

ABAIM AI Review Course

The American Board of Artificial Intelligence in Medicine (ABAIM) is hosting an AI Review Course as part of AiMed Global Summits Pre-Summit Programming. ABAIM is a nascent multidisciplinary AI advisory group of domain experts formed to provide educational content and a certification examination for healthcare participants in the course as they embark on their journey of AI in medicine. In partnership with AiMed Global Summit, ABAIM is offering a CME-accredited course led by industry experts. This one-day course is the perfect foundation for gaining an educational certification assessment in AI. With a live faculty of industry leading experts, it is not to be missed! Learn from AiMed Founder Anthony Chang, and ABAIM executives leading the way for AI in medicine, and join the conversation in developing best practices set to advance digital healthcare. The activity will be worth eightcredit hours based on the current schedule.

The AiMed 2023 Networking Reception will also take place Sunday evening.

CHOCs Chief Intelligence and Innovation Officer, Anthony Chang, MD, MBA, MPH, MS, is the Chairman and Founder of AIMed, who will join with AIMed CEO Freddy White to deliver the Grand Opening Keynote address on Monday, June 5.

The Headlines Stage, featuring expert sources on key topics daily, will kick off on day one with an address focused on AI Foundations: 2023 Update of AI in Healthcare. Presenters joining AIMed Founder Chang for this session include Alfonso Limon of Oneirix Labs,Karen B Seagraves, PhD,Sharief Taraman, MD, University of California, Irvine School of Medicine.

Official opening of the AiMed Smart Health Expo featuring vendors providing solutions, services, inspiration, as well as open floor layout for optimized networking and making connections over refreshments.

AI Foundations: a foundation level masterclass provides a multidisciplinary and comprehensive overview of the principles and application of data science, artificial intelligence and intelligence-based medicine. Covering its basic concepts and its real-life applications at a top level. This masterclass is a must attend for any clinician and practitioner seeking to strengthen their foundational level knowledge of AI.

Additionally, the Smart Health Expo opens Monday, June 5, offering an open floor plan for improved networking.Subspecialty Group Meetups will also take place on the first day of the summit.

Breakfast Workshops will allow participants to take a deep dive into a range of key areas impacting AI in medicine, from Leveraging Natural Language in Healthcare to a C-Suite Primer and additional sessions.

Breakout Tracks allow attendees to engage in all aspects impacting their work: From Data to Delivery; Ethics & Regulation; Population Health & Equity; Tools & Deployment; Strategies for Healthcare Leaders; Applications in Clinical Domains; The Computer Lab.

The Headliners Roundup for June 6 features a session, Whats Influencing Clinical Medicine and Healthcare Today? and will include Michael Howell, MD,Google Health, Jack Hampson, ofDeeper Insights, and PatricioA. Frias, MD,Rady Children's Hospital.

The Shark Tank Startup Showcase on June 6 will allow the shortlisted five start-ups four minutes to deliver a shark tank style pitch of their solution followed by six minutes for Q&A. The prestigious judging panel of healthcare entrepreneurs and VCs who invest in seed rounds will rank each pitch to determine the winner.

AI Champions Awards will presented as an evening to celebrate and recognize the great people and organizations that are helping to drive the agenda for artificial intelligence in healthcare. To be held the evening of Tuesday, June 6, the AI Champion Awards is described as an evening to celebrate and recognize the great people and organizations that are helping to drive the agenda for artificial intelligence in healthcare.

On the final day of AiMed 2023, another 15 sessions will take place, including Breakfast Workshops focused on Digital Twins, Operationalizing AI and other hot topics. Also on June 7, the AiMed Abstract Competition will give students, early and established career clinicians and data scientists the opportunity to present posters to an esteemed panel of judges.

Closing out the 3-day event on the Headliners Stage will be a series of keynotes from senior healthcare leaders. Breakout tracks covering 6 key areas will offer Stargazing AI in Healthcare: What Does the 5 Year Roadmap Ahead Look Like?

Panelists include: Anthony Chang MD, MBA, MPH, MS, of CHOC and Founder, AiMed;Eric Eskioglu, MD, MBA, formerly withNovant Health; Eric Wicklund, from mHealthIntelligence; G. Hamilton Baker, MD, of The Medical University of South Carolina;Karen B Seagraves, PhD, MPH;and William W Feaster, MD, CHOC Children's Hospital.

AiMed is described as a driving force ensuring the healthcare sector is not left behind, whose stated goals are to eradicate challenges, define AI enabled solutions and create an efficient workplace, with patient outcomes at its core. The organization notes that its aim is to assist medical professionals to discover new ways to incorporate advances in technology to help the way they work.The Childrens Hospital of Orange County (CHOC) Medical Intelligence and Innovation Institute (MI3) is funded by the Sharon Disney Lund Foundation with the purpose of advancing data science and artificial intelligence in medicine around the world. Our vision is for this institute as well as AiMed to serve as a clarion call to start a revolution to embrace this exciting new paradigm for healthcare and medicine.

For more information: https://ai-med.io

AiMed Global Summits Lineup Announced

AiMed 2023: Changing Healthcare One Connection at a Time

Find more AiMed23 conference coverage here

See the rest here:

AIMed Global Summit 2023 to Focus on Changing Healthcare One ... - Diagnostic and Interventional Cardiology

The Wistar Institute, Pennsylvania Biotechnology Center and Baruch S. Blumberg Institute Forge Strategic Collaboration to Support Regional Biotech…

Newswise PHILADELPHIA (MAY 9, 2023) The Wistar Institute has formed a new strategic collaboration with the Pennsylvania Biotechnology Center (PABC) and the Baruch S. Blumberg Institute to accelerate the advancement of bench to bedside biomedical research discoveries in the tri-state region by collectively supporting the seeding, launching and maturation of life science startups.

The Wistar Institute is a Philadelphia-based world leader in discovery science in the areas of cancer, immunology and infectious disease. The PABC is a highly successful nonprofit incubator promoting regional economic development and fostering the development of startup companies in the life sciences. The Blumberg Institute, which manages the PABC, is a nonprofit organization focused on translation research in the life sciences. The two organizations share a campus with their sister institution, the Hepatitis B Foundation, in Doylestown, Pennsylvania.

The PABC and Blumberg Institute will leverage the institutes scientists and the PABCs member companies and collaborative entrepreneurial ecosystem with Wistars growing pipeline of technologies including NK and T-Cell engaging antibodies, multivalent biologics, small-molecule oncology and immunooncology therapies, cell and gene therapies, and vaccine and diagnostic assets.

As Wistars SVP of Business Development and Executive Director of Technology Transfer Heather A. Steinman, Ph.D., MBA, explained, Through this important collaboration, we see the opportunity to leverage Wistars pre-clinical assets in both oncology and infectious diseases with PABC/BSBIs access to capital, infrastructure and life science sector talent pool to further enhance the innovation ecosystem in the region.

This collaboration will involve use of Blabs at Cira Centre, a state-of-the-art incubator in University City, which is managed by the PABC and was conceived, designed and built by Brandywine Realty Trust. Jerry Sweeney, President & CEO of Brandywine Realty Trust, said he is pleased to be furthering the advancement of Philadelphias life sciences community.

This is a welcome reminder of the powerful possibilities that collaborations like this can generate, Sweeney said. Were delighted to provide the physical platform to support the promising startups at B+labs at Cira Centre and look forward to seeing their missions become realized through this dynamic ecosystem.

Louis P. Kassa III, MPA, Chief Executive Officer of the Hepatitis Foundation, Blumberg Institute and PABC foresees this collaborative model as a prototype to attract talent, new capital and support startups more broadly throughout the Pennsylvania, New Jersey and Delaware life sciences cluster.

This agreement represents a major new chapter in the PABCs progress and the evolution of the Blumberg Institute, Kassa said. Were thrilled to be collaborating with The Wistar Institute and we see our relationship growing significantly in the years and months ahead.

Through their new collaboration, The Wistar Institute and the Pennsylvania Biotechnology Center are planning to co-host a new translational science seminar series, as well as an early-stage life sciences startup how-to seminar series for supporting trainees and entrepreneurial scientists to advance basic research discoveries to clinical therapies.

###

The Wistar InstituteThe Wistar Institute, the first independent, nonprofit biomedical research institute in the United States, marshals the talents of an international team of outstanding scientists through a culture of biomedical collaboration and innovation. Wistar scientists are focused on solving some of the worlds most challenging and important problems in the field of cancer, infectious disease, and immunology. Wistar has been producing groundbreaking advances in world health for more than a century. Consistent with its legacy of leadership in biomedical research and a track record of life-saving contributions in immunology and cell biology, Wistar scientists early-stage discoveries shorten the path from bench to bedside. wistar.org.

The Pennsylvania Biotechnology Center (PABC)The PABC uses a highly successful services-based approach to nurture and guide its member companies to success, advance biotechnology, maximize synergies among nonprofit scientists and their commercial colleagues, and launch new ideas and discoveries that will make a positive impact. The PABC has nearly 100 member companies and organizations, mostly small to mid-size science, research and pharmaceutical companies. Nearly 50 of those companies operate on the Doylestown campus, which is home to the Hepatitis B Foundation and the Blumberg Institute. The PABC also manages B+labs a Cira Centre, a new incubator in Philadelphia, in partnership with Brandywine Realty Trust. PABC companies have produced numerous FDA-approved drugs and medical devices, and a recent study found that the PABCs economic impact exceeded $7.3 billion and created more than 1,100 new jobs during 2016-2021.

The Baruch S. Blumberg InstituteAn independent, nonprofit research organization, the Blumberg Institute was launched in 2003 by the Hepatitis B Foundation to advance its research mission. Today, the Institute is one of the nations leading centers for translational research in hepatitis B and liver cancer. The Institute supports drug discovery, biomarker discovery and translational biotechnology around common research themes such as chronic hepatitis, liver disease and liver cancer in an environment conducive to interaction, collaboration and focus.

Read this article:
The Wistar Institute, Pennsylvania Biotechnology Center and Baruch S. Blumberg Institute Forge Strategic Collaboration to Support Regional Biotech...

Study Identifies Genetic Mutations That Contribute to Adult Epilepsy – Mass General Brigham

Findings point to the potential for using existing cancer therapies to treat drug-resistant epilepsy

Epilepsy affects approximately 1 in 26 people and the most common form, known as temporal lobe epilepsy (TLE), often cannot be adequately treated with anti-seizure medications. Patients with this form of epilepsy may require neurosurgery to provide relief from seizures. The conditions origins and progression are not well understood, and it has been unclear if genetic mutations may contribute to TLE. A new study by investigators from Mass General Brigham, in collaboration with colleagues at Boston Childrens Hospital, sheds new light on the role of somatic mutations in TLE DNA alterations that occur after conception and suggests the potential of using existing cancer therapies to treat TLE that is resistant to anti-seizure medications. Their results are published in JAMA Neurology.

Somatic mutations are likely an underappreciated and significant cause of neurologic diseases, particularly for epilepsy, said co-first authorSattar Khoshkhoo, MD,of the Department of Neurology at Brigham and Womens Hospital, a founding member of the Mass General Brigham healthcare system. And as an epileptologist who specifically focuses on epilepsy genetics in my clinical practice, my underlying assumption is that all epilepsy is due to genetic causes until proven otherwise. We are discovering more and more new genetic pathways in epilepsy, which is important because our goal is to offer more specific, targeted treatments for individual patients and offer guidance on who would benefit from one treatment versus the other.

Our results provide the first solid insight into this most common form of adult epilepsy, said co-senior authorChristopher Walsh, MD, PhD, of Boston Childrens Hospital. It shows that epilepsies that are not usually inherited can still be genetic in their mechanism. And the specific genetic pathway we have identified, RAS/MAPK, opens a whole new avenue of therapeutic possibilities, since anti-cancer drugs that target this pathway may have unexpected uses in epilepsy.

To uncover somatic mutations, Khoshkhoo and colleagues performed a case-control genetic association study, analyzing DNA from brain tissue samples collected from 105 patients with epilepsy and 30 controls between 1988 and 2019. The team sequenced portions of the genome coding for proteins (whole exome sequencing) and looked at specific locations in the genome (gene-panel sequencing), with each genomic region sequenced more than 500 times on average.

The team pinpointed 11 somatic mutations that were enriched in hippocampus, the region of the brain where seizures typically originate, from 11 patients with treatment-resistant TLE. All but one of the 11 mutations were connected to a specific genetic pathway known as the RAS/MAPK pathway. This finding is particularly important because several anti-cancer drugs have been developed to target the RAS/MAPK pathway. If the studys results are confirmed and validated, such drugs could be tested for the treatment of TLE. In addition to suggesting a potential path to treatment, the findings could also be used to help inform treatment decisions for patients who do or do not harbor these somatic mutations.

This work is exciting because it identifies potential drug targets that can be modulated with repurposed, FDA-approved anti-cancer agents. This suggests the potential for a rational, precision medicine treatment for a problem that we currently treat by removing a significant part of the temporal lobe with neurosurgery, saidKristopher Kahle, MD, PhD,the Nicholas T. Zervas Endowed Chair at Harvard Medical School and the chief of Pediatric Neurosurgery at Massachusetts General Hospital, a founding member of Mass General Brigham. Kahle also holds research appointments in genetics/genomics and neurosurgery at Boston Childrens Hospital.

The authors note that their study includes samples only from patients whose disease was severe enough to require surgery and may not be generalizable to patients with less severe disease. In addition, samples from these patients may have more scarring and cell death from seizures. This could mean that the somatic mutations they detected may be much more prevalent than the rates found in this study.

The investigators plan to test a larger number of hippocampus samples and use cell models to test pre-existing drugs.

Our findings point to the potential for developing the first disease modifying treatment in TLE, said Khoshkhoo. Being able to provide a genetic diagnosis has implications for clinical decision making and could signal a new day for treatment.

Disclosures:Walsh has received grants from Howard Hughes Medical Institute, National Institutes of Neurological Disease and Stroke, Allen Frontiers Group/Allen Foundation, Simons Foundation, and Templeton Foundation during the conduct of the study. Additional disclosures can be found in theJAMA Neurologypaper.

Funding:National Institutes of Health (R25-NS065743, K08-NS128272, T32-GM007753, R25-NS079198, R01-NS035129 and R01-NS094596, R01-NS094596, DP2-AG072437, R01-AG070921, R01-NS035129, R01-NS109358, R01-NS111029, R01-NS117609), Doris Duke Physician Scientist Fellowship, the Manton Center for Orphan Disease Research at Boston Childrens Hospital, a European Commissions Horizon 2020 Research and Innovation Programme Marie Sklodowska-Curie Actions Individual Fellowship (grant agreement 101026484), Australia National Health and Medical Research Council Investigator (Grant 1172897), Australia National Health and Medical Research Council Investigator (Grant 1196637), Australia National Health and Medical Research Council Ideas (Grant 2012287), Australia National Health and Medical Research Council Project (Grants 1129054 and 1079058), the Suh Kyungbae Foundation, the Allen Discovery Center program, the Allen Frontiers Program, Yale-Rockefeller Centers for Mendelian Genomics, the Simons Foundation, March of Dimes, Hydrocephalus Association, and Rudi Schulte Research Institute.

Paper cited:Khoshkhoo Set al.Contribution of Somatic Ras/Raf/Mitogen-Activated Protein Kinase Variants in the Hippocampus in Drug-Resistant Mesial Temporal Lobe EpilepsyJAMA NeurologyDOI: 10.1001/jamaneurol.2023.0473

Go here to see the original:
Study Identifies Genetic Mutations That Contribute to Adult Epilepsy - Mass General Brigham

Job shadowing steered ASU outstanding grad to dentistry – ASU News Now

May 3, 2023

Editors note:This story is part of a series of profiles of notablespring2023 graduates.

With a love of working with people and a passion for human anatomy, Arizona State University College of Integrative Sciences and Arts Class of 2023 Outstanding Undergraduate Spencer Bigler said he first thought his future path would be going to medical school, to be either an anesthesiologist or a surgeon. Accepted to every dental program he applied to, Spencer Bigler will attend Midwestern University in Arizona on a military scholarship with the U.S. Navy, then do an oral and maxillofacial surgery residency at a naval hospital before serving his country as a Navy dental surgeon. Download Full Image

But that shifted the summer between his freshman and sophomore years, when he started shadowing anesthesiologists and orthopedic surgeons.

I realized that the anesthesiologist did not do enough hands-on work for me, and the orthopedic surgeon was working 80 hours a week, making it hard for the family, said Bigler, who majored in applied biological sciences at ASU Polytechnic campus and was married at age 20 to Livi Bigler, a College of Integrative Sciences and Arts psychology major. I started second-guessing school and wondered if I should change careers altogether.

About this same time he was asked to help out during the COVID-19 lockdown at an office of general dentistry.

I didnt have much experience, but they were understaffed and being overrun by emergency appointments, he said. I noticed that many of the more complicated cases such as jaw fractures, complex sleep apnea issues and patients who had received radiation were all sent to a specialist known as an oral and maxillofacial surgeon. After looking into the field, I found out that they are trained in both dentistry and medicine, as they perform surgeries and administer general anesthesia. I decided to follow one surgeon, and when I found out he worked less than 40 hours a week and had a happy family life, I knew this was the career for me, and I have never looked back.

Bigler, who is graduating with a GPA above 4.0, has worked at a dental clinic and had many other applied dental experiences, including a weeklong dental mission trip in Mexico, from his sophomore year onward. He also has set the paperwork in motion to found a nonprofit in the Dominican Republic that provides opportunities to exchange community service work, like cleaning up streets and beaches, for health care services. Bigler was awarded funds from ASUs J. Orin Edson Entrepreneurship + Innovation Institutes pitch competition to support the organization.

This semester I interned at Arizona Maxillofacial Surgeons, where I work with some great oral and maxillofacial surgeons, he said, and Ive learned many techniques that will help me out in the future.

To round out his dental school applications and solidify his knowledge, Bigler served as a supplemental instruction leader for Chemistry 116 and continues to tutor students in chemistry and organic chemistry. He was president of the Pre-Dental Club at ASU Polytechnic campus and a volunteer with the CISA Student Ambassador program.

Still, Bigler knew that getting accepted to a great school would also rest on his ability to do well on the Dental Admission Test.

I took the exam between my junior and senior year. The five-hour test covers topics taught throughout undergrad and other topics that I had to learn outside of my school studies, he explained.

After six months of studying and practicing with other ASU pre-dental students, I took the test, hoping to get a good enough score to be competitive, Bigler said. I was shocked when I found out I scored in the 99thpercentile. I was ecstatic and knew that my dreams of becoming an oral and maxillofacial surgeon could indeed become a reality."

Indeed, he was admitted into all of his top picks for dental school.

Bigler didnt just rest on his incredible accomplishments. He is sharing his experiences to try to lift others up, explained Julie Lim, College of Integrative Arts and Sciences assistant director for student engagement.

Spencers innate desire to help others includes helping his peers here at ASU, said Lim, who coordinates theCISA Student Ambassador program and connects with many student club leaders. As president of the Pre-Dental Club, Spencer is teaching his peers about the dental field and supporting their goals of getting into dental school. Once others learned of Spencers DAT scores and admission into dental programs, he was inundated with questions and requests for tips and advice. To help as many interested individuals as possible, Spencer created a resource to address these questions.

His comprehensive guide, How to Get into Dental School from Start to Finish, is free to the public to help preprofessionals get access to the tools they need to get into dentistry. It even includes some tips that are specific to ASU students.

Bigler plans to turn it into a website by fall. I was lucky enough to have a ton of social capital around me as I prepared for dental school, he noted in the guide, and I want to make that knowledge public for anyone who is searching to have access, without having to pay any fees to get that knowledge.

Spencer has continued to amaze me as he takes steps to not only reach his goals but is also focused in how service can be tied along with his career path, added Lim. During my interactions with students, most plan and think about what they want to do in the future. Spencer, on the other hand, is doing it now.

Bigler shared these additional reflections about his ASU journey and plans for the future.

Question: Whats something you learned while at ASU in the classroom or otherwise that surprised you or changed your perspective?

Answer: ASU taught me the importance of social capital and how not everyone has equal amounts of it. Social capital is the predisposition that some people have to succeed due to their networks and social circles that can help them get where they want to get. Unfortunately, many people are born into social circles that make it hard for them to succeed, not because they are not smart enough or unwilling to work, but because they do not know where to look or who can help them. ASU taught me to not only be aware of social capital, but also contribute to society by helping spread knowledge and social capital to the general public.

Q: Why did you choose ASU?

A: Living in the Dominican Republic at the time, I had applied to three colleges for undergrad a month before classes started. The first college to reach out to me to say I was accepted was ASU, two weeks before classes started. I knew I didnt want to wait a semester to start college, so I decided that I would go to ASU. Looking back, it was one of the best decisions I have made.

Q: Which professor taught you the most important lesson while at ASU and what was it?

A: I had several professors teach me profound lessons while here at ASU. One that sticks out to me was a lesson taught by Professor Vikas Garg, who teaches organic chemistry at the Polytechnic campus. He and Ihad formed a good professor-student relationship, as I was his TA, and he helped me study for the Dental Admission Test from time to time. After class one day, we got talking about cultures and how American culture differs from the culture in India where he is from. He knew that I was independent form my parents and married by the age of 20. He told me that he thought the American culture of becoming independent at a young age has proven to be a strong driving force in the success of young American leaders. At the time I felt overwhelmed juggling school, work, family life and future career plans, so hearing a professor giving me inspiration that all my hard work was making me a better person was both comforting and eye-opening.

Q: Whats the best piece of advice youd give to those still in school?

A: Be a creator of your circumstances, not a creature. This quote was given to me as I was learning Spanish in the Dominican Republic. I kept blaming the dialect and other people for my not being able to understand and speak Spanish fluently. After hearing this quote, I realized that the power was in me to take control of my circumstances and create something good out of it.

While working at Arizona Maxillofacial Surgeons, I heard a different quote that had similar meaning behind it. When an assistant stated that there was a problem with one of the autoclaves, the surgeon responded in a calm but firm voice, Be a part of the solution, not the problem. The assistant right away understood, and rephrased the statement to say, There is a leak in the autoclave, and it appears to be the seal; may I order a new seal? This was a live examplefor me of someone who started by being a creature of their circumstance by posing a problem, then corrected themselves and became a creator of their circumstance by posing a solution. We all have the power to do this in our everyday lives. Do it and it will change the way you see the world.

Q: What was your favorite spot on campus, whether for studying, meeting friends or just thinking about life?

A: I loved going to the library and borrowing markers to use on the whiteboards. I cant count how many exciting and engaging study sessions I had with fellow Sun Devils working up problems, and making fun ways to remember topics around the whiteboards in the library.

Q: What are your plans aftergraduation?

A: Ive accepted admission to dental school at Midwestern University in Arizona on a full-ride military scholarship with the U.S. Navy. I will get my four-year education there and then plan to do an oral and maxillofacial surgery residency at a naval hospital for another four years. Then I plan to serve my country as a surgeon in the Navy for a few years before settling down and working in a private practice. While on this journey I plan to start a family with my amazing wife, Livi; invest in real estate; and participate in dental humanitarian work.

Q: If someone gave you$40millionto solve one problem on our planet, what would you tackle?

A: Last summer I went back to the Dominican Republic and noticed a need for better access to health care, as well as cleaner streets and beaches. That inspired me to start a nonprofit organization known as MATA (Making A Thriving Atmosphere). Its goal is to make a thriving atmosphere for professionals and patients by helping them get access to what they need in exchange for service. Many Dominicans do not have the money to get the health care they want but have plenty of free time and are always in search of a job. MATA will find service opportunities that fit patients physical capabilities that they can do in exchange for treatment and access to health care.With $40 million I would be able to go further than I imagined by helping people in more countries than just the Dominican Republic, and reach out to other facets in health care outside of dentistry.

Continue reading here:

Job shadowing steered ASU outstanding grad to dentistry - ASU News Now

Real Madrid and Abbott inaugurate the Innovation Lab – Real Madrid

Located at the first-team facilities at Real Madrid City, the centre will be home to research into sports nutrition and physiology.

Real Madrid andAbbott have launched their Innovation Lab, a space for the Real Madrid Medical Services and Abbott's scientists to collaborate in creating innovative ideas and exploring the future of nutrition and physiology in sports.The centre is located in the first-team facilities atReal Madrid Cityand it's a project aimed at enhancing our players' performance.The collaboration will originate seminars, conferences and studies like the one conducted by Abbott and Real Madrid, and published in the specialist scientific magazineFrontiers, which deals with the role of biomarkersin aiding an understanding of player fatigue and recovery.The ultimate goal is for the work carried out at the Innovation Lab to help the medical teams devise optimised nutrition protocols to boost sporting performance.

See the original post here:
Real Madrid and Abbott inaugurate the Innovation Lab - Real Madrid